This bill addresses concerns that Pharmacy Benefit Managers (PBMs) currently operate with little transparency, making it difficult for health plans and consumers to understand how prescription drug costs are determined. PBMs negotiate drug prices and rebates with manufacturers, and the current system allows for a lack of clarity on how these savings are passed on, if at all, to health plans and patients.
If this bill becomes law, PBMs would be legally obligated to prioritize the financial interests of health plans and their members, similar to a financial advisor managing someone's investments. This change could lead to PBMs negotiating more aggressively for lower drug costs and ensuring that more of the savings from rebates are passed on to plans and patients. Without this bill, the current system of limited transparency and accountability for PBMs is likely to continue, potentially contributing to higher prescription drug costs for many Americans.
KEY PROVISIONS
4AI-extracted
PROVISION 01
Defines Pharmacy Benefit Managers (PBMs) as fiduciaries under ERISA for group health plans, meaning they must act solely in the best interest of the plan and its beneficiaries.
This significantly increases the legal responsibility and accountability of PBMs in managing prescription drug benefits.
PROVISION 02
Requires PBMs and Third-Party Administrators (TPAs) to disclose all direct and indirect compensation they receive for services provided to group health plans.
This aims to bring transparency to the complex financial arrangements, including rebates and fees, that influence prescription drug costs.
PROVISION 03
Prevents PBMs (that are fiduciaries under this new definition) from using contractual agreements to avoid liability for breaches of their fiduciary duties.
This ensures PBMs cannot escape responsibility if they fail to uphold their legal obligations to health plans.
PROVISION 04
Specifies that a PBM or TPA cannot be considered the "responsible plan fiduciary" for the purpose of the new disclosure requirements, with a narrow exception for PBMs sponsoring their own employee plans.
This ensures independent oversight of the required compensation disclosures, preventing conflicts of interest.
This bill addresses concerns that Pharmacy Benefit Managers (PBMs) currently operate with little transparency, making it difficult for health plans and consumers to understand how prescription drug costs are determined. PBMs negotiate drug prices and rebates with manufacturers, and the current system allows for a lack of clarity on how these savings are passed on, if at all, to health plans and patients.
If this bill becomes law, PBMs would be legally obligated to prioritize the financial interests of health plans and their members, similar to a financial advisor managing someone's investments. This change could lead to PBMs negotiating more aggressively for lower drug costs and ensuring that more of the savings from rebates are passed on to plans and patients. Without this bill, the current system of limited transparency and accountability for PBMs is likely to continue, potentially contributing to higher prescription drug costs for many Americans.
KEY PROVISIONS
AI-extracted
high
Defines Pharmacy Benefit Managers (PBMs) as fiduciaries under ERISA for group health plans, meaning they must act solely in the best interest of the plan and its beneficiaries.
This significantly increases the legal responsibility and accountability of PBMs in managing prescription drug benefits.
high
Requires PBMs and Third-Party Administrators (TPAs) to disclose all direct and indirect compensation they receive for services provided to group health plans.
This aims to bring transparency to the complex financial arrangements, including rebates and fees, that influence prescription drug costs.
med
Prevents PBMs (that are fiduciaries under this new definition) from using contractual agreements to avoid liability for breaches of their fiduciary duties.
This ensures PBMs cannot escape responsibility if they fail to uphold their legal obligations to health plans.
med
Specifies that a PBM or TPA cannot be considered the "responsible plan fiduciary" for the purpose of the new disclosure requirements, with a narrow exception for PBMs sponsoring their own employee plans.
This ensures independent oversight of the required compensation disclosures, preventing conflicts of interest.
Beginning with the first plan year that begins at least 12 months after the date of enactment of this Act.
The amendments made by this section shall apply with respect to plan years.
GLOSSARY
AI-written
Pharmacy Benefit Manager (PBM)
A company that manages prescription drug benefits for health insurance plans, employers, and other organizations. They negotiate drug prices, process claims, and create drug lists.
Fiduciary
A person or company that has a legal and ethical obligation to act in the best interest of another party, putting that party's interests ahead of their own.
ERISA (Employee Retirement Income Security Act)
A federal law that sets minimum standards for most voluntarily established retirement and health plans in private industry to provide protection for individuals in these plans.
Group Health Plan
A health insurance plan offered by an employer or employee organization that provides medical care to employees and their families.
Rebate Aggregator
A company that collects rebates from drug manufacturers, often on behalf of multiple PBMs or health plans, usually in exchange for placing drugs on their preferred lists.
Formulary
A list of prescription drugs covered by a health insurance plan. It typically categorizes drugs by cost and coverage levels.
Third-Party Administrator (TPA)
ACTION TIMELINE
2 EVENTS
DEC 17, 25
Introduced in Senate
INTROREFERRAL
DEC 17, 25
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
An organization that processes claims and handles other administrative tasks for a self-funded health plan, but does not assume the financial risk for paying claims.
